Atriumfibrilleren Boezemfibrilleren
Conditions
Interventions
Use of Accenocoumarol, Apixaban and Dabigatran
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patient must meet all of the following criteria: • Male or female >= 18 years • AF with stable coronary disease (either angiographically proven, undergone an intervention or history of MI) • Use of OAC(NOAC) • Patients with signed informed consent
Exclusion criteria
Exclusion criteria: • Patients who are unable to give informed consent • Patients with hematologic, renal (estimated glomerular filtration rate 2 times the upper limit of normal), inflammatory (CRP >2 times the upper limit of normal)or neoplastic disorders • Patients using any other antithrombotic drugs (e.g., aspirin, GPIIbIIIa etc.) • Patients using nonsteroidal anti-inflammatory drugs, corticosteroids, or hormone replacement therapy • Patients with valvular AF(either articfial heart valves, medium to severe mitral valve stenosis or
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Percentage platelet bound P-selectin expression | — |
Secondary
| Measure | Time frame |
|---|---|
| • Levels of Tromboxane B2 • Platelet reactivity as measured with multiple platelet function tests (Appendix A) • Fibrinolysis activity as measured with Plasmin-antiplasmin complex (PAP), D-dimers and TAFIa levels as well as in vitro clot-lysis time between the three drugs will be contrasted. • Fibrin formation markers (fibrinopeptide A and B and soluble fibrin) and the in vitro clotting time • Overall thrombus formation and clot lysis assessment using thromboelastography (TEG) en T-TAS | — |
Countries
Netherlands
Outcome results
None listed